Amylyx Pharmaceuticals, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Amylyx Pharmaceuticals details Q2 2026 financial performance, highlighting increased R&D and SG&A expenses, while advancing its pipeline candidates avexitide and AMX0035.
NASDAQ
Amylyx Pharmaceuticals reports increased R&D spending and a net loss for Q1 2026, with cash reserves projected to last into 2028.
NASDAQ
Amylyx Pharmaceuticals reports Q3 2025 results, highlighting a strategic pivot to its pipeline assets, avexitide, AMX0035, and AMX0114, following the discontinuation of RELYVRIO/ALBRIOZA.
NASDAQ
Amylyx Pharmaceuticals reports significant losses following the discontinuation of its lead commercial product, RELYVRIO, while advancing new investigational therapies with positive early clinical data and securing fresh capital.
NASDAQ
Amylyx Pharmaceuticals reports a net loss for Q1 2025 and focuses on advancing its pipeline following the discontinuation of RELYVRIO/ALBRIOZA.
NASDAQ
10-Q: Amylyx Pharmaceuticals Reports Q3 2024 Results, Focuses on Pipeline After ALS Drug Discontinuation
Amylyx Pharmaceuticals reports a net loss for Q3 2024 and focuses on its pipeline after discontinuing its ALS drug, RELYVRIO/ALBRIOZA.
NASDAQ
10-Q: Amylyx Pharmaceuticals Reports Q2 2024 Results, Focuses on Pipeline After RELYVRIO Discontinuation
Amylyx Pharmaceuticals reported its Q2 2024 results, highlighting a strategic shift towards its pipeline programs following the discontinuation of RELYVRIO/ALBRIOZA.
NASDAQ
Amylyx Pharmaceuticals announced its Q1 2024 results, a restructuring plan, and the voluntary discontinuation of marketing authorizations for RELYVRIO/ALBRIOZA following disappointing Phase 3 trial results.